This article is more than 5 years old. Information may no longer be current.

Rocket Pharmaceuticals posts $19.6 million annual net loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Rocket Pharmaceuticals, which recently merged with Inotek Pharmaceuticals, reported a net loss of $19.6 million, or $219.49 per share, in 2017 compared with a net loss of $7.6 million, or $84.43 per share, in 2016, according to a press release.

Research and development costs increased from $6 million in 2016 to $14.9 million in 2017, while general and administrative costs increased to $4.9 million in 2017 compared with $1.6 million in 2016.

The company had $18.1 million in cash as of Dec. 31, 2017. As of Feb. 28, after the Inotek merger and a common stock offering, it had cash, cash equivalents and short-term stock of $185 million.